BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2025 9:41:58 AM | Browse: 306 | Download: 645
 |
Received |
|
2025-05-16 10:27 |
|
Peer-Review Started |
|
2025-05-20 00:11 |
|
First Decision by Editorial Office Director |
|
2025-06-04 03:30 |
|
Return for Revision |
|
2025-06-04 03:30 |
|
Revised |
|
2025-06-16 08:53 |
|
Publication Fee Transferred |
|
2025-06-20 10:15 |
|
Second Decision by Editor |
|
2025-08-08 09:20 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-08-15 10:46 |
|
Articles in Press |
|
2025-08-15 10:46 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-09-03 01:03 |
|
Publish the Manuscript Online |
|
2025-09-11 09:41 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Basic Study |
| Article Title |
Farrerol ameliorates diabetic cardiomyopathy by inhibiting ferroptosis via miR-29b-3p/SIRT1 signaling pathway in endothelial cells
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yan Guo, Xin-Rou Yu, Hao-Di Gu, Yu-Jie Wang, Zhen-Gang Yang, Ju-Fang Chi, Liu-Ping Zhang and Hui Lin |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Medical Health Science and Technology Project of Zhejiang Provincial |
2025KY1721 and 2022KY1292 |
| Science and Technology Projects of Shaoxing City |
2022KY104 |
|
| Corresponding Author |
Hui Lin, MD, PhD, Department of Cardiology, The Affiliated Lihuili Hospital of Ningbo University, No. 57 Xingning Road, Yinzhou District, Ningbo 315211, Zhejiang Province, China. 122525790@qq.com |
| Key Words |
Diabetic cardiomyopathy; Microvascular dysfunction; Farrerol; MiR-29b-3p; SIRT1 |
| Core Tip |
This study was the first to identify the miR-29b-3p/SIRT1 axis as a critical mechanism underlying the attenuation of endothelial ferroptosis and microvascular dysfunction of farrerol (FA) in diabetic cardiomyopathy (DCM). These results highlight the translational potential of targeting miR-29b-3p or administering FA for the treatment of DCM. |
| Publish Date |
2025-09-11 09:41 |
| Citation |
Guo Y, Yu XR, Gu HD, Wang YJ, Yang ZG, Chi JF, Zhang LP, Lin H. Farrerol ameliorates diabetic cardiomyopathy by inhibiting ferroptosis via miR-29b-3p/SIRT1 signaling pathway in endothelial cells. World J Diabetes 2025; 16(9): 109553 |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i9/109553.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i9.109553 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
